Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

By G. Aithal, James A Thomas, P. Kaye, A. Lawson, S. Ryder, I. Spendlove, A. Austin, J. Freeman, L. Morgan, J. Webber. Gastroenterology, 2008

734 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Five randomized controlled trials are available [203–207], which are heterogenous for drugs and dosages, duration of treatment, categories of patients included and histological outcomes [208].”
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “124 128 Interestingly, a recent meta-analysis of eight RCTs (including a total of 516 adults with biopsy-confirmed NASH) showed that pioglitazone improved advanced fibrosis in NASH, even in patients without diabetes.”
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, methodology): “A liver biopsy to establish a diagnosis of NASH should be obtained before starting children on pharmacological therapy for NASH.”
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 (2010, background): “Thiazolidinediones also reduce liver fat and are effective in treating non-alcoholic steatohepatitis [139, 191].”